Welcome to our dedicated page for PETVIVO HOLDINGS WTS news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on PETVIVO HOLDINGS WTS stock.
PETVIVO HOLDINGS INC WTS (symbol: PETVW) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. With a strategic approach of leveraging investments in human biomaterials and medical device industries, PETVIVO aims to bring therapeutics to pets in a capital and time-efficient manner. The company's core strategy involves in-licensing proprietary products from human medical device companies for pet use. PETVIVO HOLDINGS INC WTS is the parent company of petvivo, inc, gel-del technologies, inc, and cosmetalife corporation.
Rhea-AI Summary
PetVivo Holdings, Inc. (PETV) to dual list shares on Upstream for global trading starting March 5, 2024. Shareholders to receive commemorative NFT. Upstream offers real-time trading, transparent orderbook, and digital collectibles for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. will showcase its innovative veterinary medical device, SPRYNG™ with OsteoCushion™ Technology, at the Western Veterinary Conference. The conference, hosting over 15,000 participants, offers a platform for PetVivo to engage with industry professionals and promote its joint pain management solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (Nasdaq: PETV) announces financial results for the third quarter of 2024, highlighting a multi-distribution sales strategy and the addition of a new Board member. The company raised $1.2 million in a private offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. announced the release of the results of a clinical study conducted by Inotiv, Inc., which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates (Spryng™ with OsteoCushion™ Technology) into the joints of cats. The study demonstrated the excellent safety profile of Spryng when injected into 40 joints across 10 individual cats, showing similar results to a benign control in terms of incidences of lameness, joint swelling, or pain after injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. will report financial results on February 12, 2024, after market close. The company is focused on commercializing innovative medical therapeutics for animals. A conference call to discuss the results will be held at 4:00 p.m. CT (5:00 p.m. ET) on the same day. The webcast and earnings release materials can be accessed on PetVivo’s Investor Relations website. PetVivo uses its Investor Relations website to disclose material nonpublic information and comply with its disclosure obligations under Regulation FD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. announces the results of a clinical study examining the safety of intra-articular injections of a collagen-elastin hydrogel microparticulate biomaterial into the joints of dogs. The study demonstrated the safety profile of the veterinary medical device, Spryng with OsteoCushion Technology, in managing joint-related afflictions in companion animals. The data provided from the study indicates that the use of Spryng was similar to a benign control in regard to incidences of lameness, joint swelling, or pain after injection, with post-injection outcomes often no different than pre-injection baseline measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. announces the issuance of a notice of allowance for a patent application by the United States Patent and Trademark Office (USPTO) related to the Company’s proprietary biomaterials and corresponding products. The patent provides protection for a broad range of proprietary products, including the biocompatible sponge-like particles used in PetVivo’s signature product, Spryng™ with OsteoCushion™ Technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
News
Rhea-AI Summary
PetVivo Holdings, an emerging biomedical device company (NASDAQ: PETV & PETVW), will exhibit its lead product, Spryng with OsteoCushion Technology, at the Veterinary Meeting & Expo Conference from January 14th to 17th, 2024. The intra-articular injectable veterinary medical device is designed to manage joint-related afflictions such as osteoarthritis, and the company aims to network with industry leaders at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has entered into a definitive distribution agreement with Covetrus North America, LLC to market and promote its veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout the United States. Covetrus sales and marketing activities will commence on January 1, 2024. This strategic partnership aims to benefit the veterinary industry, the veterinarians, the animals receiving Spryng, and the owners benefiting from the enhanced medical outcomes of their animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
News
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) achieved a significant milestone by distributing over 4500 syringes of Spryng™ with OsteoCushion™ technology to veterinarians in 2023. This represents a 60% increase from the previous year. The positive outcomes experienced by animals injected with Spryng have driven its momentum, with high enthusiasm from veterinarians and upcoming clinical studies and trade show exposure expected to further boost distribution in the new year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.46%
Tags
FAQ
What is the current stock price of PETVIVO HOLDINGS WTS (PETVW)?
The current stock price of PETVIVO HOLDINGS WTS (PETVW) is $0.0256 as of October 1, 2024.
What does PETVIVO HOLDINGS INC WTS specialize in?
PETVIVO focuses on licensing and commercializing innovative medical devices for pets, also known as pet therapeutics.
What is PETVIVO's strategic approach?
The company leverages investments in human biomaterials and medical device industries to efficiently bring therapeutics to pets.
How does PETVIVO commercialize products for pets?
PETVIVO in-licenses proprietary products from human medical device companies specifically for pet use.
What subsidiaries are under PETVIVO HOLDINGS INC?
petvivo, inc, gel-del technologies, inc, and cosmetalife are all wholly-owned subsidiaries of PETVIVO HOLDINGS INC.
What is PETVIVO's core business model?
PETVIVO's core model involves commercializing innovative medical devices for pets through strategic partnerships.
What is the significance of PETVIVO in the biomedical device industry?
PETVIVO plays a crucial role by bringing human medical advancements to the pet therapeutics sector.
How does PETVIVO ensure efficient commercialization of pet therapeutics?
PETVIVO's strategy focuses on in-licensing products from human medical device companies, streamlining the process.
What sets PETVIVO apart in the pet therapeutics market?
PETVIVO's unique approach of leveraging human medical device technology for pets sets it apart in the industry.
What are some recent achievements of PETVIVO HOLDINGS INC WTS?
PETVIVO has successfully partnered with leading human medical device companies to bring cutting-edge therapeutics to pets.
What can investors expect from PETVIVO's future projects?
Investors can anticipate further advancements in pet therapeutics through PETVIVO's ongoing projects and collaborations.
PETVIVO HOLDINGS INC WTS